[{"id":"80df7b6e-ddde-4bae-9a86-d126eca09c34","acronym":"EMR 200066-006","url":"https://clinicaltrials.gov/study/NCT01390818","created_at":"2021-01-18T05:42:31.509Z","updated_at":"2024-07-02T16:37:24.658Z","phase":"Phase 1","brief_title":"Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT01390818 - EMR 200066-006","lead_sponsor":"EMD Serono","biomarkers":" EGFR • HER-2 • KRAS • BRAF • NRAS • PTEN • KIT • GNAQ • GNA11","pipe":"","alterations":" ","tags":["EGFR • HER-2 • KRAS • BRAF • NRAS • PTEN • KIT • GNAQ • GNA11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pimasertib (AS703026) • voxtalisib (SAR245409)"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 05/01/2011","start_date":" 05/01/2011","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2017-03-07"},{"id":"e56b349a-b69a-4109-9846-e2fd6587dab1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01082068","created_at":"2021-01-18T04:16:01.865Z","updated_at":"2024-07-02T16:37:31.533Z","phase":"Phase 1/2","brief_title":"Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer","source_id_and_acronym":"NCT01082068","lead_sponsor":"Sanofi","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • pilaralisib (SAR245408) • voxtalisib (SAR245409)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/01/2013","study_completion_date":" 04/01/2013","last_update_posted":"2016-06-03"}]